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Essure (Bayer) received approval from the U.S. Food and Drugs Administration as a permanent non-hormonal contraceptive implant in Novem-
ber 2002. While the use of Essure in the management of hydrosalpinx prior to in vitro fertilization (IVF) remains off-label, it has been used spe-
cifically for this purpose since at least 2007. Although most published reports on Essure placement before IVF have been reassuring, clinical ex-
perience remains limited, and no randomized studies have demonstrated the safety or efficacy of Essure in this context. In fact, no published 
guidelines deal with patient selection or counseling regarding the Essure procedure specifically in the context of IVF. Although Essure is an irre-
versible birth control option, some patients request the surgical removal of the implants for various reasons. While these patients could eventu-
ally undergo hysterectomy, at present no standardized technique exists for simple Essure removal with conservation of the uterus. This article 
emphasizes new aspects of the Essure procedure, as we describe the first known association between the placement of Essure implants and 
the subsequent development of fluid within the uterine cavity, which resolved after the surgical removal of both devices.
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Introduction
The standard recommendation for the surgical correction of hydro-
salpinx before in vitro fertilization (IVF) assumes that the patient is a 
suitable candidate for laparoscopy. This may not always be the case. 
For example, extensive pelvic adhesions and an increased risk for 
bowel injury may make abdominal access unsafe or difficult for some 
patients. In contrast, the hysteroscopic management of hydrosalpin-
ges has important advantages over laparoscopy, such as obviating 
the need for abdominal access, reducing the overall cost, and mini-
mizing anesthesia requirements. These features have led the office 
hysteroscopic Essure (Bayer, Whippany, NJ, USA) procedure to be 
considered an attractive non-incisional alternative to traditional lapa-
roscopic tubal surgery for women with hydrosalpinx before IVF. Most 
published descriptions of the use of Essure to treat hydrosalpinx be-
fore embryo transfer have been favorable. Indeed, the reported com-
plications following Essure placement have mainly occurred in the 
context of its Food and Drugs Administration-approved birth control 
application [1,2], not in a pre-IVF setting.
Data are unavailable regarding how often Essure is placed before 
IVF, or what proportion of Essure patients ultimately seek IVF after 
undergoing a tubal occlusion procedure. This is the first known re-
port to describe a case of abnormal endometrial fluid collection after 
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Essure placement one year before IVF was planned. Once the devices 
were surgically excised, the intrauterine fluid disappeared. We pres-
ent some novel counseling considerations regarding Essure when 
used for this purpose and also outline a successful surgical technique 
for the intact removal of the Essure device.
Case report
A 42-year-old unmarried nulligravida presented for a reproductive 
endocrinology consultation; the patient was in good general health, 
had regular menses, and had never smoked. Her body mass index 
was 22 kg/m2. At the time of her initial appointment, she had under-
gone Essure placement 1 year previously and stated her wish to un-
dergo IVF with anonymous donor gametes. Many years earlier, she 
experienced ‘chronic belly pain’ for which multiple specialists were 
seen, and eventually she underwent a total colectomy at age 28. Pel-
vic adhesions were later suspected, based on a hysterosalpingogram 
(HSG) that showed distal occlusion in both fallopian tubes. Twelve 
years after partial bowel resection, the patient underwent bilateral 
Essure placement for the management of hydrosalpinges. She re-
mained asymptomatic after the Essure procedure, but a confirmatory 
HSG was not performed. 
At our center, an intrauterine fluid collection measuring approxi-
mately 5.7 mm (in the anterior-posterior dimension) was identified 
and confirmed on three separate transvaginal sonograms obtained 
at various phases of the patient’s menstrual cycle. No evidence of 
tubal pathology was found on the ultrasound images. A representa-
tive sample of this fluid was aspirated on the final sonogram visit and 
was submitted for analysis; no organisms or abnormal cytological 
findings were identified. The potential negative impact of the uterine 
fluid on the outcome of IVF was carefully discussed with the patient.
All of the patient’s screening tests, cervical cytology, and pre-IVF 
laboratory testing were normal. However, her serum anti-Müllerian 
hormone level was < 0.16 ng/mL, suggesting poor ovarian reserve. 
The patient reviewed anonymous oocyte donor profiles, contacted 
an anonymous sperm bank, and written informed consent was ob-
tained for IVF using dual anonymous donor gametes. The patient 
completed psychological counseling, and a favorable report was re-
turned. However, her treatment could not begin until the problem of 
endometrial compartment fluid was resolved. While laparoscopic 
and hysteroscopic routes for Essure removal were considered, the 
patient was advised that hysteroscopic removal would probably fail 
in her case since far more than 12 weeks had elapsed since the im-
plants were placed [3]. The patient was carefully counseled about the 
risks associated with laparoscopy. 
Informed consent was obtained for hysteroscopy, laparoscopy, lap-
arotomy (in case of emergency), the removal of foreign objects, and 
partial bilateral salpingectomy. A bowel preparation was ordered pri-
or to surgery, and a colorectal surgeon and gynecologic oncologist 
were on stand-by to assist with the abdominal portion of the opera-
tion if needed. Under general anesthesia, the uterine cavity was eval-
uated via a 5-mm video hysteroscope. The endometrial cavity was 
normal and the uterotubal junctions were easily visualized. Full de-
vice engraftment was noted bilaterally and no exposed coils were 
seen. Attention was next turned to the abdomen, which was safely 
entered on the first attempt and explored laparoscopically. Two 
5-mm accessory ports were placed under direct video laparoscopic 
guidance. Moderate adhesions were noted at the proximal left fallo-
pian tube, although the uterine exterior and both ovaries appeared 
unremarkable.
Bipolar cautery set to 40 W of power was used sparingly to desic-
cate the outer tissue layers of the right fallopian tube near the right 
uterine junction. The tissue was carefully divided in a circumferential 
fashion down to the level of the implant. The Essure implant and the 
associated tubal tissue were isolated carefully from the cornual place-
ment site, and any exterior uterine bleeding was easily managed 
with electrocautery. In order to avoid traction on the device, resis-
tance to lateral movement was met with more extensive uterine dis-
section to facilitate lifting the implant away from the cornu, rather 
than pulling the device out of it. Once the tube and its attached Es-
sure implant were freed from the uterotubal junction, the outer coil’s 
terminal marker (Figure 1) was closely inspected to ensure that the 
device had been removed intact. With the medial portion of the Fal-
lopian tube now unattached, the lateral extent of the implant was 
observed through serial palpation with an atraumatic grasper. Cau-
tery was applied to the fallopian tube approximately 1 cm lateral to 
the distal margin of the Essure implant. This freed the device and its 
associated tubal tissue for en bloc removal; no linear salpingotomy 
was performed. Next, the contralateral tube was examined and 
treated with the bipolar cautery tool. Tissue desiccation was again 
achieved with 40 W of power in a similar fashion to remove an equiv-
alent tubal segment contralaterally. Both adnexal sites were carefully 
examined and excellent hemostasis was noted. No vasoconstrictive 
solution was injected at either operative site. The patient tolerated 
the procedure well and no complications occurred; she was dis-
charged home in less than 4 hours. Her immediate postoperative 
course was uneventful. Three weeks after surgery, pelvic ultrasound 
confirmed that the uterine fluid had resolved. Six months after the 
laparoscopic removal of the Essure implants, pelvic MRI was per-
formed and was normal, with no signs of contour defect, no retained 
Essure fragments, or residual fluid collection. The patient continues 
to do well, and her planned embryo transfer was postponed for per-
sonal reasons.
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Discussion
In IVF patients, fluid collections within either the fallopian tube(s) or 
endometrial compartment are well-known negative prognostic fac-
tors for reproductive outcomes. Although the exact mechanism re-
mains unknown, the harmful effect of hydrosalpinx fluid may be due 
to the retrograde flow of embryotoxic substances into the endome-
trial compartment, the possibility that the fluid could mechanically 
flush or dislodge embryos after transfer, or both. Even in the absence 
of tubal pathology, fluid within the endometrial compartment is still 
detrimental to embryo implantation [4]. Although the standard 
management approach for the problem of hydrosalpinges before 
embryo transfer is laparoscopic surgery, a non-incisional hysterosco-
py-based technique (Essure) has gained attention in recent years. As 
experience increases with Essure—and most published reports have 
been favorable—important questions regarding patient counseling, 
informed consent, post-Essure monitoring, and even techniques for 
implant removal require attention.
Some studies have indicated that it can be useful for selected IVF 
patients with hydrosalpinges to undergo the Essure procedure as a 
non-incisional alternative to laparoscopy [5]. Most research on Essure 
used in this way has focused on comparing the efficacy of Essure 
with the standard laparoscopic management of tubal disease. A re-
cent Spanish study reported on 15 IVF patients for whom laparosco-
py was contraindicated, and their outcomes were compared with pa-
tients undergoing laparoscopy [5]. The IVF pregnancy rates after Es-
sure were slightly—but not significantly—lower than in the laparo-
scopic salpingectomy group, although this may not have been due 
to the Essure device per se, but rather because the ovarian reserve 
was lower among Essure patients [5].
The persistent endometrial fluid observed in the present case led to 
a recommendation for Essure removal before planned embryo trans-
fer, although exactly how the Essure device may have caused this 
buildup of uterine fluid remains unclear. Considering the mechanism 
of action of Essure when it functions as a tubal contraceptive implant, 
it is possible that the inflammation is not limited to the immediate vi-
cinity of the tubal ostia. This would seem more likely to be a problem 
when the proximal portion of the implant remains within the uterine 
cavity, as recommended by the manufacturer. Of course, if IVF were 
anticipated, this issue could be attenuated by ensuring that no im-
plant component protruded medially past the tubal ostium (e.g., by 
positioning the Essure device completely within the fallopian tube). 
While this technique has not been standardized, a ‘deep Essure place-
ment’ if IVF is planned has been proposed [6], in contrast to how Es-
sure is inserted when used for conventional tubal sterilization [7].
According to the manufacturer’s guidelines, bilateral tubal occlu-
sion must be confirmed 3 months after Essure device placement by a 
HSG. By this time, fibrosis of the proximal Fallopian tubes has oc-
curred, which leads to tubal occlusion and yields the desired contra-
ceptive effect. Thus, patients must use a back-up method of birth 
control for at least 3 months after the Essure procedure. If at that 
point bilateral tubal occlusion is not confirmed on a HSG, the patient 
should continue to use an alternative method of contraception for 
three more months. Pregnancies that have occurred after hystero-
scopic sterilization with Essure have been explained by lack of follow-
up HSG, the improper use of alternative contraception, the failure of 
alternative contraception, or the misinterpretation of HSG results. Of 
note, a recent investigation of unplanned pregnancies with Essure 
revealed that 66% of contraceptive failures occurred among women 
who were compliant with their post-procedure HSG [8].
As of 2013, fewer than 15 cases of Essure removal have appeared in 
the global medical literature. While most removals are performed 
Figure 1. (A) Pre-placement view of an Essure contraceptive implant, depicting the inner rod (arrow) and the terminal marker for the outer Ni-
tinol coil (circle). (B) An intraoperative photograph showing intact surgical excision of the device, including the inner rod (arrow) and the outer 
coil terminal marker (circle).
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within 12 weeks of the initial insertion [3], no consensus exists regard-
ing the preferred surgical approach to “late” Essure removal. For our 
patient, we used a modified Albright technique [3], in which laparo-
scopic partial bilateral salpingectomy was performed without salpin-
gotomy. We agree that careful assessment of the tubal anatomy 
should take into account the exact alignment of the Essure device 
with respect to the surrounding tubal tissue. The length of the Essure 
device is 4 cm, and its distal end should therefore reside at the tubal 
isthmus, assuming proper insert placement and no migration. 
Effecting an en bloc resection (i.e., removing the device while still 
within its associated tubal tissue), eliminates the need to expose the 
full Essure implant to the extreme temperatures from electrocautery. 
Given the polyethylene terephthalate (PET) component of Essure, we 
chose to use cautery sparingly during laparoscopy. The production of 
PET involves the catalytic use of antimony, which can still be found 
on product surfaces post-production. While this residue can be re-
moved by irrigation, antimony remains in the Essure device itself and 
may dissipate under certain conditions. Extrapolating from experi-
mental work in anon-surgical context, drinking water sold in plastic 
bottles containing PET can, when heated, release worrisome levels of 
leached antimony [9]. Accordingly, subjecting the Essure device to 
prolonged heat could increase antimony exposure [10], thus poten-
tially dispersing this hazardous vapor throughout the abdominopel-
vic cavity. Our experience suggests that the Essure device can remain 
intact as long as the bipolar energy does not exceed 40 W of power. 
Since this approach had never before been attempted, even though 
the implants appeared grossly intact at surgery, a pelvic magnetic 
resonance image obtained within 30 days of removal indicated that 
complete extraction was achieved and no Essure fragments were re-
tained. While magnetic resonance imaging up to a magnetic field 
strength of 1.5 T is not contraindicated for patients with Essure, a 
postoperative HSG or ultrasound may provide similar reassurance 
with comparable sensitivity.
While Essure may be considered for sterilization when laparoscopy 
is contraindicated, little clinical experience has been reported of the 
use of Essure as a treatment for hydrosalpinges before IVF. To be sure, 
most Essure placements before IVF reported to date have been suc-
cessful; but no consensus exists about how to evaluate, counsel, and 
obtain informed consent from such patients. If the Essure procedure 
becomes more common for hydrosalpinges in the future, a standard-
ized approach to informed consent should be developed. Unfortu-
nately for our patient, after undergoing the Essure procedure, the 
problem of hydrosalpinx fluid was replaced with a different prob-
lem—endometrial compartment fluid. The development of Essure-
associated intracavitary fluid that was corrected after Essure removal 
suggests additional points for consideration regarding the use of this 
device before planned IVF.
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